Peter A. von dem Borne

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis

Peter A. von dem Borne, JC Meijers, BN Bouma · Blood · 1995 · 292 citations · Full text

Medicine, Molecular Biology, Physiology +17

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman et al. · Blood · 2009 · 275 citations · Full text

Medicine, Hematology, Oncology +17

Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Peter A. von dem Borne, Laszlo Bajzar, Joost C.M. Meijers et al. · Journal of Clinical Investigation · 1997 · 233 citations · Full text

Medicine, Biochemistry, Molecular Biology +14

Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation

Peter A. von dem Borne, Joost Meijers, Bonno N. Bouma et al. · Thrombosis and Haemostasis · 1998 · 218 citations

Medicine, Biochemistry, Clinical Biochemistry +13